The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression.

MLA

Xiao, Li, et al. “The Use of Selective Immunosuppressive Therapy on Myelodysplastic Syndromes in Targeted Populations Results in Good Response Rates and Avoids Treatment-Related Disease Progression.” American Journal of Hematology, vol. 87, no. 1, Jan. 2012, pp. 26–31. EBSCOhost, https://doi.org/10.1002/ajh.22184.

APA

Xiao, L., Qi, Z., Qiusheng, C., Li, X., Luxi, S., & Lingyun, W. (2012). The use of selective immunosuppressive therapy on myelodysplastic syndromes in targeted populations results in good response rates and avoids treatment-related disease progression. American Journal of Hematology, 87(1), 26–31. https://doi.org/10.1002/ajh.22184

Chicago

Xiao, Li, Zhu Qi, Chen Qiusheng, Xu Li, Song Luxi, and Wu Lingyun. 2012. “The Use of Selective Immunosuppressive Therapy on Myelodysplastic Syndromes in Targeted Populations Results in Good Response Rates and Avoids Treatment-Related Disease Progression.” American Journal of Hematology 87 (1): 26–31. doi:10.1002/ajh.22184.